PPARγ as a therapeutic target in cystic fibrosis

Cystic fibrosis (CF) is characterized by a proinflammatory pulmonary condition that may result from increased infections and altered intracellular metabolism in CFTR-deficient cells. The lipid-activated transcription factor peroxisome proliferator-activated receptor-gamma (PPAR gamma) has well-established roles in immune cell function and inflammatory modulation and has been demonstrated to play an important role in the heightened inflammatory response in CF cells. Here, we summarize current literature describing PPAR gamma-dependent alterations of CF cells and discuss the potential of PPAR gamma ligands for treating CF.